Skip to main content

Crispr Therapeutics AG (CRSP) Receives a Buy from JMP Securities

TipRanks - Mon Jul 11, 11:16PM CDT
In a report released today, Silvan Tuerkcan from JMP Securities maintained a Buy rating on Crispr Therapeutics AG (CRSPResearch Report), with a price target of $100.00. The companys shares closed last Monday at $73.71.

According to TipRanks.com, Tuerkcan is a 2-star analyst with an average return of 0.7% and a 39.6% success rate. Tuerkcan covers the Healthcare sector, focusing on stocks such as Turning Point Therapeutics, Intellia Therapeutics, and Logicbio Therapeutics.

Currently, the analyst consensus on Crispr Therapeutics AG is a Moderate Buy with an average price target of $98.94.

See the top stocks recommended by analysts >> The company has a one-year high of $146.96 and a one-year low of $42.51. Currently, Crispr Therapeutics AG has an average volume of 1.9M. TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities. CRISPR Therapeutics AG engages in the development and commercialization of therapies derived from genome-editing technology. Its proprietary platform CRISPR/Cas9-based therapeutics allows for precise and directed changes to genomic DNA. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan and Craig Mellow in 2014 and is headquartered in Zug, Switzerland. Read More on CRSP:

Paid Post: Content produced by TipRanks. The Globe and Mail was not involved, and material was not reviewed prior to publication.